Geographical variation in prevalence of hepatitis B virus DNA in HBsAg negative patients


Abstract

Aims—To study the geographical variation of the prevalence of hepatitis B virus (HBV) DNA in hepatitis B surface antigen (HBsAg) negative subjects.

Methods—A nested polymerase chain reaction (PCR) assay was used to amplify the core region of HBV. The assay was able to detect 10 molecules of a full length HBV plasmid.

Results—When applied to HBsAg negative paraffin wax embedded liver samples from Italy, Hong Kong, and the United Kingdom, a geographical variation in the prevalence of HBV-DNA positivity was noted. Two of 18 (11%) of Italian samples and 2/29 (6.9%) of Hong Kong samples were positive for HBV-DNA while none of the 70 cases from the United Kingdom was positive by nested PCR. Contamination by plasmid DNA was excluded using a novel method based on heteroduplex formation. One HBV-DNA positive case had idiopathic chronic active hepatitis, but the diagnoses in the other three HBV-DNA positive cases did not suggest any aetiological connection between HBV-DNA positivity and liver pathology.

Conclusions—HBV-DNA could be detected in the liver tissues of a proportion of HBsAg negative subjects. The prevalence of such cases is related to the endemic rate of a geographical region. The use of HBV PCR on paraffin wax embedded tissues will be valuable for future studies on the molecular epidemiology of HBV.

(J Clin Pathol 1993;46:304-308)

Hepatitis B virus (HBV) infection is a major public health problem, with an estimated carrier population of over 200 million world wide.1 Diagnosis used to be based solely on serology, but development of molecular biology has led to the generation of data inconsistent with conventional serology, such as the detection of HBV-DNA in a significant proportion of patients with hepatitis B surface antigen (HBsAg) negative chronic liver disease.2,3 Subsequently, however, other investigators failed to confirm these observations.4,5 The development of the polymerase chain reaction (PCR)7 has allowed these studies to be repeated using a method with exquisite sensitivity.8 The use of the PCR, however, has not resolved the above controversy in that some investigators have succeeded in amplifying HBV-DNA from HBsAg negative individuals9,10 while others have failed to do so.11 One explanation might be differences in methodologies used by different laboratories, but another reason might be a geographical difference in HBV virology—the endemic rate.

To address this important question, we benefited from the ability of the PCR to amplify from paraffin wax embedded liver tissues12,13 which can be transferred easily from country to country. We used a modification of the basic amplification system called nested PCR. This has been shown to be as sensitive as PCR followed by Southern blotting, and yet has the added advantages of being non-isotopic and rapid.14 Using this approach, we examined paraffin wax embedded liver tissues from HBsAg negative subjects from three geographical regions: two high incidence areas (Hong Kong and Italy) and one low incidence area (United Kingdom).

Methods

HBsAg TESTING
Patients were tested for serum HBsAg by a radioimmunoassay (Abbott Laboratories; Chicago, Illinois) in Milan and enzyme linked immunosorbent assays (ELISA) in Hong Kong (using an assay produced by Abbott Laboratories) and Oxford (using an assay produced by Biokit). Orcein staining was done for all liver samples; none stained.

PREPARATION OF PARAFFIN WAX EMBEDDED SECTION FOR PCR
Paraffin wax embedded liver tissues from HBsAg negative subjects were randomly chosen from material collected between 1988 and 1991 stored in the pathological archives of participating centres from three geographical localities. One to 10 5 μm sections were cut from paraffin wax blocks and placed in a 1.5 ml Eppendorf tube. Each tube contained liver tissues with a total volume of 2 cm² × 5 μm. Subsequent processing was essentially as described before.15 In brief, the sections were dewaxed in 400 μl xylene (Aldrich, HPLC grade), vortexed for 1 minute, and spun for 5 minutes (Microcentaur). The xylene was pipetted off and its residue was removed with 400 μl of 95% ethanol. This was followed by vortexing (1 minute) and...
spinning (5 minutes). Most of the ethanol was pipetted off and a second 95% ethanol wash was performed. Most of the ethanol was removed and the rest was removed by incubating in an 80°C oven for 10 minutes. One hundred microlitres of digestion buffer (50 mM TRIS, pH8.5, 1 mM EDTA, 0.5% Tween 20; Sigma) with 200 μg/ml proteinase K (Boehringer Mannheim) was added to each tube. Digestion with proteinase K was allowed to proceed overnight at 37°C.

After digestion the tube was spun briefly and heated to 94°C for 20 minutes to inactivate the proteinase K. Ten microlitres were then used for PCR assay.

**Figure 1** Sensitivity of HBV-PCR assay. Serial dilutions of a plasmid containing a full-length HBV insert (pHBV130) were amplified by PCR. Results after both the first and the second round are shown. The approximate number of target molecules in the lanes are: lane 1, 107; lane 2, 107; lane 3, 10^5; lane 4, 10^5; lane 5, 10; lane 6, 1; lane 7, 0.01; lane 8, 0.01; lane 9, blank (negative control). M denotes φX174 DNA digested with HaeIII (marker). 270 and 258 denote the sizes in base pairs of the first and second round PCR products, respectively.

**POLYMERASE CHAIN REACTION**

The PCR was carried out as described. Reagents were obtained from a GeneAmp DNA Amplification Reagent Kit (Perkin-Elmer Cetus). PCR was performed in 50 μl reactions with 1.25 units of Tag polymerase (Perkin-Elmer Cetus). DNA amplification was carried out using a Biometra Trio Thermoblock. After an initial denaturation step at 95°C for 3 minutes subsequent cycling profile was 94°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute.

Each sample was first amplified using primers PC03 and PC04 specific to the β-globin gene. Forty cycles of PCR were carried out. Only samples producing a positive β-globin signal were amplified using HBV primers. The nested PCR system20 for the core gene of HBV consisted of 40 cycles of first round PCR using primers 1763 and 2032R (PCR product size: 270 base pairs). Two microlitres of the first round PCR products were then reamplified for 25 cycles using primers 1778E and 2017RB (PCR product size: 258 base pairs).

Primer sequences are listed below:

PC03: 5'ACACAACGTGGTTTACTAGC 3'
PC04: 5'CAACTTCTACAGTTCATACC 3'

1763: 5'GCTTTGGGGCATGGACATTG-1750
2032R: 5'TGACTACTAATTCCTGG-ATGCTGTGCCTT 3'

1778E: 5'GACGAAATTCCATTTGACC-GTGTCCTGAC 3'
2017RB: 5'ATGGGATCCCTGGATGCT-3'

**ANALYSIS OF AMPLIFIED DNA**

Ten to 20 μl of the PCR products were run on a 1.5% agarose gel. DNA was visualised by ultraviolet fluorescence after staining with ethidium bromide.

**PREVENTION AND DETECTION OF CONTAMINATION**

To minimise the risk of contamination, all of the previously published guidelines were observed. As a plasmid containing a full-length HBV insert (pHBV130) was used as a positive control in the PCR experiments, contamination by PCR products from the plasmid was potentially possible. Exclusion of plasmid PCR products as the source of contamination was carried out using the recently described heteroduplex method. Thus all PCR products from test samples were mixed with an equimolar amount of the PCR product from pHBV130, denatured at 94°C for 5 minutes and reannealed at 65°C for 5 minutes. The mixtures were cooled to 4°C for 10 minutes before being run on a 10% non-denaturing polyacrylamide gel in TBE (0.089 M TRIS, 0.089 M boric acid, 2 mM EDTA, pH8.0). In the presence of sequence differences between the PCR products from the test samples and that from the plasmid, heteroduplexes would be seen, and thus contamination by plasmid derived DNA could be excluded. Conversely, if no heteroduplexes

**Figure 2** Amplification of β-globin sequences from paraffin wax embedded tissues. Lanes A to P are results of PCR amplification of a β-globin genomic sequence from a series of formalin fixed, paraffin wax embedded liver biopsies from Hong Kong. Failed amplifications are seen in lanes H, I, and P. Lane Q is the negative control (blank). Arrows indicate position of the 110 base pair β-globin PCR product.
were observed, contamination tracing back to pHBV130 could not be excluded.

Results
SENSITIVITY OF HBV PCR SYSTEM
To determine the sensitivity of the nested HBV PCR system, serial dilutions of a plasmid containing a full-length HBV insert (pHBV130) were made in water. After 40 cycles of first round PCR, a signal was visible in an ethidium stained gel for 10⁵ molecules (fig 1). After 25 cycles of second round PCR the detection limit was extended to the equivalent of 10 molecules (fig 1). This sensitivity was similar to that previously reported by Kaneko et al.³

AMPLIFICATION OF β-GLOBIN SEQUENCES FROM WAX EMBEDDED TISSUES
Due to the existence of inhibitors in certain paraffin wax embedded tissues, PCB amplification of β-globin genomic sequences was attempted in all tissue samples of the 33 HBsAg negative cases obtained from Hong Kong. Twenty nine (88%) cases produced a β-globin signal. Representative data are shown in fig 2. Of the 20 HBsAg negative cases obtained from Italy, 18 (90%) gave rise to a β-globin signal. Of the 80 HBsAg negative cases obtained from the United Kingdom, 70 (88%) cases produced a β-globin signal. The proportion of cases giving successful β-globin amplification was consistent with our earlier observations.²¹ These cases were then chosen for amplification using the nested HBV PCR system.

Discussion
The nested PCR system used was sensitive, rapid, and completely non-isotopic. The sensitivity of the method was such that 10 molecules of HBV DNA could be detected.

The presence of PCR inhibitors in paraffin wax embedded tissues required the prior exclusion of samples which were refractory to PCR. This demonstrated the importance of the β-globin positive control. The proportion of samples which were refractory to PCR ranged from 10–12% and was consistent with previous observations.

Our data confirmed previous observations...
that HBV DNA could be detected in a proportion of HBsAg negative subjects.\textsuperscript{1-12} Furthermore, the proportion of such cases seems to be related to the endemic rate of HBV infection in a geographical region. Thus in high incidence areas such as Milan and Hong Kong, with a carrier rate of 3-5\%\textsuperscript{22} and 9-6\%\textsuperscript{21} respectively, the percentages of HBV DNA positive cases were 11\% and 6-9\%, respectively. The HBsAg positive carrier rate in London has been estimated at 0-5\%\textsuperscript{24} and the carrier rate in Oxford is likely to be much lower. We have not been able to detect any HBV DNA in any of the 70 cases from the United Kingdom. It should be noted that our figures for HBV DNA positivity in Milan and Hong Kong should be regarded as gross estimates because the numbers involved are too small to provide a precise figure on the prevalence. Nevertheless, the difference in HBV DNA prevalence between the high and low incidence areas is highly significant.

The commercially available tests for HBsAg used in this study were radioimmunoassay or ELISA based and these assays had a sensitivity of < 0-5 ng/ml.\textsuperscript{25} In a direct comparison between the three assays, the ELISA made by Biokit was not as sensitive as the radioimmunoassay and ELISA manufactured by Abbott Laboratories (Dr J Kurtz, John Radcliffe Hospital, personal communication). The assay used in Oxford would therefore bias our results in that we may have missed some cases with low concentrations of HBsAg. Hence the observation that none of the Oxford cases was positive by PCR is highly significant.

Our data, however, did not provide conclusive evidence of an aetiological link between HBV DNA positivity and the liver pathology seen. Interestingly, one Italian case diagnosed as having idiopathic chronic active hepatitis was shown to have HBV DNA by nested PCR. HBV could potentially have been the cause of liver pathology in this case. However, for the other three cases (porphyria cutanea tarda, secondary adenocarcinoma, and non-specific changes), the role of HBV was less clear. Nevertheless, these data show that HBV is present in a proportion of HBsAg negative subjects which may have public health implications in high incidence areas.

Some investigators have used multiple primer sets for HBV detection by PCR; others have used only one set of primers.\textsuperscript{12} The use of multiple primer sets might increase the detection rate of HBV-DNA in our samples, but we do not think that this will alter our basic conclusions. Our belief is based on the relatively large sample size of our study (117 cases in total) and the fact that the primer combination we used has been used before to detect HBV DNA in HBsAg negative subjects.\textsuperscript{11,12}

Finally, the heteroduplex method\textsuperscript{28} we used to exclude contamination due to cloned viral DNA has been confirmed to be reliable and rapid. The differences in mobility of heteroduplexes from different cases shown in fig 4 were consistent with a previous report showing a 2–15\% difference in nucleotide sequence in the core gene amplified from different HBV isolates.\textsuperscript{17} We envisage that this method could be widely applied in many virological laboratories. Furthermore, the method could potentially be modified for typing viruses.

We thank the Wellcome Trust and Foulkes’ Foundation Fellowship for financial support. We also thank Dr Eric Yap and Dr J Kurtz for helpful discussion.

Geographical variation in prevalence of hepatitis B virus DNA in HBsAg negative patients.

Y M Lo, E S Lo, W Z Mehal, M Sampietro, G Fiorelli, G Ronchi, C H Tse and K A Fleming

doi: 10.1136/jcp.46.4.304

Updated information and services can be found at:
http://jcp.bmj.com/content/46/4/304

**Email alerting service**

_These include:_

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/